Opinion

We have a national dementia plan. So where are the results? | Opinion

An effective strategy must connect three priorities: reducing risk, supporting care, and advancing treatment, says Paul Shemella.
Agence France-Presse

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held ...

Rope, twine and thread: Invisible technologies of the Stone Age

When an abstract-looking ivory artifact emerged from the Hohle Fels cave in southern Germany in 2015, archaeologists didn't ...

What is a Human? - The Genealogy of Homo XX

When examined, a fairly large composition comes into view. Homo economicus, the idea that "humans are beings that maximize ...
Rutland Herald

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Takeda ( TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, ...

The Two Wheels Needed in the Era of the 40-Year-Old Retirement System: A Design for Cultivating 'Expertise' and 'Human Skills' Simultaneously

Relying solely on specific expertise carries the risk of obsolescence and commoditization. It is a 'trap of expertise,' a ...

Akeso, Inc.: Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class ...
Cancer Network

Real-World Tislelizumab Combo Shows Encouraging Efficacy in ES-SCLC

“This multicenter real-world study suggests that first-line tislelizumab combined with platinum-etoposide chemotherapy provides encouraging efficacy with an acceptable safety profile in patients with ...